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Abstract
Background: 177Lu is used in peptide receptor radionuclide therapies for the treatment of neuroendocrine tumors.
Based on the recent literature, SST2 antagonists are superior to agonists in tumor uptake. The compound OPS201 is
the novel somatostatin antagonist showing the highest SST2 affinity. The aim of this study was to measure the in
vivo biodistribution and dosimetry of 177Lu-OPS201 in five anesthetized Danish Landrace pigs as an appropriate
substitute for humans to quantitatively assess the absorbed doses for future clinical applications.
Results: 177Lu-OPS201 was obtained with a specific activity ranging from 10 to 17 MBq/μg. Prior to administration,
the radiochemical purity was measured as s > 99.7 % in all cases. After injection, fast clearance of the compound
from the blood stream was observed. Less than 5 % of the injected activity was presented in blood 10 min after
injection. A series of SPECT/CT and whole-body scans conducted until 10 days after intravenous injection showed
uptake mostly in the liver, spine, and kidneys. There was no visible uptake in the spleen. Blood samples were taken
to determine the time-activity curve in the blood. Time-activity curves and time-integrated activity coefficients were
calculated for the organs showing visible uptake. Based on these data, the absorbed organ dose coefficients for a
70-kg patient were calculated with OLINDA/EXM. For humans after an injection of 5 GBq 177Lu-OPS201, the highest
predicted absorbed doses are obtained for the kidneys (13.7 Gy), the osteogenic cells (3.9 Gy), the urinary bladder
wall (1.8 Gy), and the liver (1.0 Gy). No metabolites of 177Lu-OPS201 were found by radio HPLC analysis. None of the
absorbed doses calculated will exceed organ toxicity levels.
Conclusions: The 177Lu-OPS201 was well tolerated and caused no abnormal physiological or behavioral signs. In
vivo distributions and absorbed doses of pigs are comparable to those observed in other publications. According to
the biodistribution data in pigs, presented in this work, the expected radiation exposure in humans will be within
the acceptable range.
Keywords: Neuroendocrine tumor (NET), Dosimetry, Antagonist, JR11, OPS201, Pig model, Lutetium-177, PRRT
Background
The radionuclide 177Lu (Lutetium-177) is being increas-
ingly used in targeted radionuclide therapy (TRT) because
of its favorable decay characteristics and the possibility of
reliable labeling of biomolecules used for tumor targeting.
Initially, 177Lu was used in a colloidal form for interstitial
injections for intraperitoneal radioimmunotherapy of
ovarian cancer [1]. Furthermore, 177Lu is increasingly used
in radioimmunotherapy (RIT) clinical trials to label differ-
ent kinds of monoclonal antibodies [2]. Presently, the
most frequent clinical use of 177Lu is in peptide receptor
radionuclide therapy (PRRT) for treatment of neuroendo-
crine tumors (NETs), in some cases parallel to or in
conjunction with 90Y [3–7].
The radiolabeled somatostatin receptor (SST2) ago-
nists DOTA-[Tyr3]octreotate (DOTATATE), DOTA-
[Tyr3]octreotide (DOTATOC), and DOTA-[NaI3]octreo-
tide (DOTANOC), as well as the antagonists OPS2011
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and OPS2022 are successfully implemented in the clin-
ical routine for imaging and treatment of NETs which
are overexpressing the somatostatin receptor SST2. The
peptidic vector connects directly to the relevant recep-
tors, and consequently, 111In-radiolabeled octreotide was
used firstly for diagnostic purposes [8] whereas the
combination with 177Lu or 90Y is used for PRRT [5, 9].
Currently, for the diagnosis and staging of NETs, 68Ga-
radiolabeled DOTA-somatostatin analogues combined
with PET/computed tomography (CT) is considered as
state of the art. However, due to the short half-life of
68Ga (1.13 h), a pretherapeutic dose assessment is chal-
lenging. In addition, the use of different radiopharma-
ceuticals in therapy and diagnostics may cause
misestimating. Therefore, further correlation studies are
necessary.
The application of SST2 agonists for TRT involves the
systemic administration of a radiolabeled peptide de-
signed to target overexpressed receptors on tumor cells
with high affinity and specificity [5, 7, 10, 11]. Contrary
to the paradigm that internalization and the resulting ac-
cumulation of radiotracers in cells is necessary for effi-
cient tumor targeting, recent preclinical and clinical
studies have indicated that antagonists are superior to
the agonist especially for tumor targeting despite little to
no internalization in cells [7, 10, 12]. OPS201 is a novel
SST2 antagonist which, to the best of our knowledge,
has the highest tumor to organ dose ratios and tumor
detection comparied to other SST2 antagonists [13].
Radiolabeled SST2 antagonists are not yet well estab-
lished for tumor targeting mainly because they do not
internalize into tumor cells [10].
However, based on the recent in vitro preclinical and
human studies, it was shown that the uptake of SST2
antagonists is higher compared to SST2 agonists [10, 11,
13, 14], although the absorbed dose to the kidneys, the
main organ at risk after treatment of NETs with DOTA-
labeled compounds, was around 50 % higher for the an-
tagonist as compared to the agonist 177Lu-octreotate [2].
For assessing the absorbed doses in humans in poten-
tial clinical applications, guidelines require the investiga-
tion of the biodistribution of 177Lu-OPS201 in an animal
model. Since pigs show similar biodistribution and phys-
ical properties to humans and because their sizes fit a
human SPECT/CT scanner, they were chosen in this
study to determine the effect of the radiotracer on the
kidneys and other organs at risk. In addition, pig studies
have the advantage of long follow-up times similar to
human studies.
Up to now, one clinical human study and one preclinical
mouse model study have been conducted with 177Lu-
DOTA-JR11 (OPS201) [10, 12]. In the first human pilot
study with 177Lu-DOTA-JR11 (OPS201) by Wild et al.
[10], the efficacy of 177Lu-OPS201 was demonstrated by
therapy response. The patients in this study already had
grade 2 or 3 chronic renal failure. A sixfold higher tumor-
to-kidney ratio was observed for 177Lu-DOTA-JR11
(OPS201) compared to 177Lu-DOTA-octreotate in spite of
1.5 times higher kidney doses for 177Lu-DOTA-JR11
(OPS201). The significant uptake of 177Lu-DOTA-octreo-
tate in the kidneys requires supplemental investigation. In
addition, comparable results to the pilot human study
were reported in the mouse model study by Dalm et al.
[12]. In this study, mice received one therapeutic injection
of 177Lu-DOTA-JR11 (OPS201) and experiments were
done in a rather short follow-up time especially for quan-
tification of the biodistribution and dosimetry [2].
Therefore, the aim of the present study was to meas-
ure the biodistribution of 177Lu-OPS201 in pigs as a
model to quantitatively assess the absorbed doses in
humans in potential clinical applications. Pigs were
chosen as they mimic humans’ physiology better than
small animals such as mice or rats. In addition, pigs
allow for multiple blood samples as well as dosimetry as-
sessment during a long period.
Methods
Physical properties of 177Lu
The radionuclide 177Lu has a 6.647-day half-life and dis-
integrates by beta-emission (probability, 100 %) to the
ground state and to the three excited levels of 177Hf. The
maximum beta energy is 498 keV. There are two gamma
emissions that have 208.3 keV photon energies with a
probability of 10.38 % per disintegration and 112.9 keV
(6.2 %). 177Lu-labeled compounds show many advan-
tages for dosimetry assessments due to attractive phys-
ical properties which comprise low abundance of
photons for sufficient post-therapy imaging, a clearly
separated gamma peak at 208.3 keV, and a low range of
beta particles. Due to its low photon abundance of emis-
sion probability, even with a 7 GBq amount of activity, it
allows the post-therapeutic imaging with avoiding cam-
era dead-time related effects which is only possible with
high activities [2].
Labeling of 177Lu-OPS201
177Lu-OPS201 was produced on an automated cassette-
based synthesis system (E&Z Modular-Lab PharmTra-
cer). The OPS201 precursor (24 nmol, Octreopharm Sci-
ences GmbH) was reacted with a non-carrier added
(n.c.a.) 177LuCl3 (Isotope Technologies Garching GmbH
(ITG)) in a sodium acetate/ascorbate buffer (pH 4.5) at
80 °C for 20 min, subsequently purified by C18 SPE, was
reformulated in an ethanol-saline solution and sterile
filtered. The radiolabeled product was stored overnight
at 4 °C. The ready-to-inject formulation was allowed to
equilibrate to room temperature for a minimum of 1 h
before administration. Quality control of the
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radiolabeled test substance was performed after the syn-
thesis and immediately before administration to confirm
its stability.
Animal study
For analyzing the biodistribution and internal dosimetry
of 177Lu-labeled peptides in preclinical and clinical stud-
ies, the mean activity 105 MBq (97–113 MBq) 177Lu-
OPS201 were injected to five anesthetized Danish Land-
race pigs (three females and two males, age 3 months,
weight 25–32 kg). All animals originated from a specific-
pathogen-free farm, where all animals were regularly
tested for infectious agents (bacteria and virus).
The animals underwent up to 7 days of acclimatization
prior to study start. The body weights of the animals
were recorded. All animals were confirmed to be in good
health.
Anesthesia was induced with Zoletil 50 Vet mixture (a
mixture of two dissociative anesthetics (ketamine
6.25 mg/mL and tiletamine 6.25 mg/mL), a benzodiazep-
ine (zolazepam 6.25 mg/mL), a synthetic opioid (butor-
phanol 1.25 mg/mL), and xylazine (6.5 mg/mL), an
alpha 2 adrenergic agonist, containing sedative, hypnotic,
analgesic, and muscle-relaxing properties). Anesthesia
was maintained with continuous intravenous infusions
of midazolam and fentanyl based on the clinical
demand.
After anesthesia, a cuffed Charriere 6.5 endotracheal
tube was inserted (Potex, Smiths Medical, Watford, UK)
and connected to an Oxylog® 2000 ventilator (Dräger
Medical GmbH, Lübeck, Germany). Normoventilation
was obtained using a volume controlled ventilation
mode with tidal volumes of 6–8 mL/kg, respiratory fre-
quency of 12–14/min, and positive end expiratory pres-
sure (PEEP) of 5 cm H2O. The settings were adjusted to
the level of end-tidal CO2. The exact levels of pH, CO2,
and potassium were tested in arterial blood samples
(ABL 800, Radiometer, Copenhagen, Denmark). The in-
spired oxygen fraction was 60 %. The animals were pro-
tected with blankets against hypothermia.
A 7-French central venous catheter was inserted into a
jugular vein for medications and fluid. A 5-French cath-
eter was inserted in the femoral artery for blood pressure
monitoring and arterial blood sampling. Continuous
blood pressure and ECG were monitored using Datex-
Ohmeda S/5 (GE Healthcare, Broendby, Denmark). A
bladder catheter was inserted for continuous urinary
drainage except in pig 4. All pigs, except pig 4, received
an intravenous amino acid infusion (28.5 g/L L-
arginine·HCl, 29.3 g/L L-lysine·HCl, 2.7 g/L NaCl) for
approximately 4 h, starting approximately 1 h prior to
the intravenous injection of 177Lu-OPS201. Since the
catheter could not be inserted for pig 4 and any urinary
drainage during the 4 h amino acid infusion combining
with 177Lu-OPS201 would directly cause 177Lu related
radiation contamination of the scanner, no amino acid
was administered to pig 4. Although in normal clinical
case all patients will receive an amino acid infusion, we
assessed to investigate the impact of amino acid infusion
on the absorbed doses. On the following days 2, 4, and
6, no arterial line was inserted. Blood samples were
taken from the ear.
Blood and urine sampling and processing
After administration, 12 arterial blood samples were taken
at nominal time points of 0.5, 1, 2, 5, 10, 20, 30, 50, 75,
100, 200, and 300 min to determine the time-activity
curve of the blood. In addition, three venous blood sam-
ples were drawn at 2, 4, 6, and 10 or 12 days after injec-
tion. The blood samples at 30, 50, 100, 200, and 300 min
and 2, 4, 6, and 10 or 12 days were used for metabolite
analysis. From the whole blood samples, 1 mL of the
whole blood was transferred into a counting tube, and the
rest was centrifuged to obtain plasma. From the plasma,
1 mL was transferred into a counting tube. Both sets of
tubes (whole blood and plasma) were analyzed in a
gamma counter normalized to measure 177Lu-OPS201.
All samples were measured, and the activity was decay-
corrected to the time of sampling. Plasma samples (1 mL)
were denatured with acetonitrile (1 mL) and centrifuged,
and the supernatant (0.5 mL) was diluted with water
(1 mL) for HPLC (high-performance liquid chromatog-
raphy) analysis. A reference sample in the form of non-
radioactive OPS201 was eventually added, and 1 mL of
the (spiked) solution was transferred into the HPLC loop
for analysis.
Urine was collected for up to 4 h post-injection of
177Lu-OPS201, using a urine catheter. The weight of the
collected urine was measured, and three 1 mL aliquots
of the urine sample were analyzed in a gamma counter
(PerkinElmer, 2480 Wizard). Urine samples (1 mL) were
analyzed directly by HPLC.
Imaging and reconstruction
SPECT/CT data and whole-body (WB) planar images
were acquired on a SIEMENS Symbia T16 (SIEMENS
AG). On day 0, three WB and SPECT/CT scans were
performed in the first 3 h. Further scans were done at 2,
4, 6, and 12 days (pigs 1 and 2) and at 2, 4, and 10 days
(pigs 3–5) after administration of approximately
105 MBq 177Lu-OPS201. The acquisition duration was
50 min for all nuclear medicine scans: 10 min for whole-
body and 40 min whole-body SPECT (2 bed positions of
20 min each). In addition, a 5 min CT was performed
for attenuation correction.
The physiological parameters of the animals were
monitored and, if necessary, adjusted during the scans.
For reconstruction, CT-based attenuation correction and
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triple-energy-window based scatter corrections were ap-
plied. The images were reconstructed with the FLASH-
3D iterative reconstruction algorithm with six iterations
and six subsets. The resulting images were smoothed
with a 6 mm Gauss filter.
Dosimetry analysis
Quantification of activity in VOIs and integration of the
time-activity curves
To quantify the amount of activity, the average percent-
age values corresponding to the injected radioactivity
(%A) per organ as a function of time were calculated for
the heart, liver, right kidney, left kidney, bladder, spine,
and WB for each pig via a manual volume of interest
(VOI) analysis (see Fig. 1). All VOIs were drawn based
on the CT scan. In order to avoid spill-out effects, CT-
based organ VOIs were enlarged as matching 2 voxel
plus their actual CT-based volumes. The whole-body up-
take of the first scan was set to 100 %. The time-activity
curves (TACs) for the blood were analyzed separately
from the collected samples, and the blood time-activity
curves (decay-corrected to the time of injection) were
fitted using Graph Pad Prism (6.07). Blood-based dosim-
etry as a surrogate for the bone marrow was performed
according to the Shen method [15].
For internal dosimetry, the organ-specific time-
integrated activity coefficients (TIACs) were calculated
by integration of the respective TACs for each organ and
blood using the software solution NUKFIT [16], choos-
ing the optimal fit functions as proposed by the code.
The TIAC is estimated by analytically integrating the fit-
ted functions. Its standard error is determined assuming
Gaussian error propagation. For this investigation, a sys-
tematic error in activity quantification of 10 % was
assumed.
The TIACs of the urinary bladder contents were inte-
grated by using a trapezoidal integration method and as-
suming physical decay after the last data point. The
TIAC of bone was calculated based on the approach that
19 % of the total skeleton mass is considered as the mass
of the spine [10]. No inter-species scaling was performed
while calculating the TIACs and TACs.
By using the values of the TIACs for a selected group
of organs, the absorbed dose coefficients for a male pa-
tient were calculated by using OLINDA/EXM [17].
Results
Labeling of 177Lu-OPS201
177Lu-OPS201 was obtained in three batches with a spe-
cific activity ranging from 10 to 17 MBq/μg. The radio-
chemical purity was determined by reversed phase
HPLC at the end of synthesis (EOS) and just prior to ad-
ministration to be always >99.7 %. The values of the
blood and plasma activity based on the serial blood
Fig. 1 Three-view display of the VOI analysis for the selected organs (pig 2, day 2)
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samples collected for up to 12 days post-dosing,
expressed in Bq/mL (decay-corrected to the time of
sampling) as well as in %IA/mL (percentage injected ac-
tivity per volume of blood, decay-corrected to the time
of injection) is provided in Additional file 1: Table S1.
The results of denatured plasma samples analyzed by
HPLC for the detection of radioactive metabolites are
also shown in Additional file 1: Table S2). No metabo-
lites could be detected. During the 4 hours of arginine
infusion plasma, potassium rose in all pigs from normal
values (3.9–4.1 mmol/L up to 7.0 mmol/L); however, un-
expectedly, it also rose to 6.6 mmol/L in pig 4 that did
not receive arginine for renal protection. On the next
day, all pigs had normal values of potassium. Hypothet-
ically, the possible explanation associated with the rise
in plasma potassium could be either impaired Na/K
pump function or a partial blockage of oxygen to the
cells resulting in a depression of the Na/K pump and the
feeling of oxygen-lack triggered hyperventilation. In
other words, the rise in plasma potassium level may be
highly related to stress.
Biodistribution and dosimetric calculations
The image quality of the WB planar scans of all pigs was
sufficient for a dosimetric analysis (for pig 1 displayed in
Fig. 2). Even after 10 days, there was still a detectable
kidney uptake. Figure 3 shows the resulting TACs for
the same animal (pig 1). The measured organ uptake
values were shown in Additional file 1: Table S3. The or-
gans with the highest uptake were the bone and kidneys,
followed by the liver. The resulting TIACs are summa-
rized in Table 1. The highest TIACs were observed for
the bone, kidneys, and liver (mean TIACbone, 11 ± 9.9 h;
mean TIACkidney, 9.4 ± 3.6 h; mean TIACliver, 4.2 ±
1.2 h). There was no visible uptake in the spleen; how-
ever, the uptake in the kidneys, spine, and bone were
easily distinguished in the WB planar scan on all the
scan days (see Fig. 2). A fast clearance of the compound
from the blood was observed in the first minutes after
administration resulting in less than 5 % of the injected
activity per liter of blood circulating 10 min after the in-
jection. 177Lu-OPS201’s blood clearance followed a biex-
ponential pattern with an initial rapid decrease (T½ α =
2.0 ± 0.9 min; 80.1 ± 3.5 % clearance in the α phase),
followed by an excretion-related blood clearance (T½
β = 36 ± 13 min). In pigs infused with an amino acid
solution (n = 4), 23.4 ± 3.5 % of the decay-corrected
activity was excreted in the urine during 4 h post-
injection. No metabolites of 177Lu-OPS201 were de-
tected by radio HPLC analysis of the plasma and
urine samples. The complete list of the corresponding
mean absorbed doses is provided in Table 2. The
highest absorbed dose coefficients were observed in
the kidneys (2.73 mGy/MBq), the osteogenic cells
(0.79 mGy/MBq), the urinary bladder wall (0.35 mGy/
MBq), and the liver (0.20 mGy/MBq). The range of
kidney absorbed doses for pigs 1–3 and 5 was 1.8–
2.7 Gy/GBq, and the kidney dose value of pig 4 was
4.5 Gy/GBq most likely due to lack of amino acid infusion.
The kidney absorbed dose value of pig 4 was not elimi-
nated from the mean absorbed dose calculation in order
to provide a conservative assessment of the absorbed dose
to the kidneys. The separated absorbed doses for each pig
related to the selected organs are shown in Table 2. None
of the absorbed doses exceeded organ toxicity levels
(23 Gy critical organ dose for kidneys [18]).
For humans after an injection of 5GBq 177Lu-OPS201,
the highest absorbed doses are obtained for the kidneys
(13.7 Gy), the osteogenic cells (3.9 Gy), the urinary blad-
der wall (1.8 Gy), and the liver (1.0 Gy).
In comparison to a diagnostic human study with 68Ga-
OPS202 (68Ga-NODAGA-JR11) [19], spine uptake was
Fig. 2 The posterior whole-body scans of pig 1 at the subsequent days after injection of 177Lu-OPS201. Scan duration of WB planar images was
10 min. The image quality of WB planar scans with 177Lu-OPS201 was high; kidney, spine, and bone uptake were easily distinguished in all days
of WB planar scan
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observed and taken into account as source organ (“skel-
eton”) in the dose calculations. In addition, no absorbed
dose to the spleen was reported in the present pig study.
Absorbed doses of 177Lu-OPS201 were calculated by
using the mean TIACs. Pig 4 was included in the mean
TIAC calculation. Although there is an overestimation
of absorbed doses associated with pig 4, we did not
reach any organ toxicity level. The results with and with-
out including pig 4 were added in the relevant figure
and table legends. Based on the dosimetric calculations
in our pig study, the predicted absorbed doses for
humans are not expected to exceed organ toxicity levels
for an injection of 5–8 GBq of 177Lu-OPS201.
Radioactive metabolites analyses
Urine and serial blood samples were collected for up to
12 days post-dosing and used to measure levels of radio-
activity in blood and plasma, and for analysis of radio-
active metabolites. No metabolites could be detected by
radio HPLC both in urine excreted during anesthesia
post-dosing (day 0) or in any of the blood samples.
Discussion
In our study, we administered approximately 105 MBq
(±8 MBq) 177Lu-OPS201 to Danish Landrace pigs. The
bone and the kidneys were potential organs at risk; how-
ever, the organs with the highest absorbed doses were
well below the critical organ doses [18]. Due to inter-
species differences, spine uptake and lack of spleen up-
take were observed in pigs in comparison to humans.
For extrapolation from animals to humans, there are
empirical approaches (same biodistribution approach or
body surface area (BSA)) and allometric approaches (rela-
tive mass scaling). Since our study focuses on in vivo bio-
distribution and dosimetry, the appropriate extrapolation
method would be relative mass scaling in which the spe-
cific activity in a human organ is set equal to the specific
activity in the same animal organ multiplied by the ratio
of the body mass of a human and an animal. In the rela-
tive mass scaling, the calculated organ mass ratios of a
Fig. 3 Time-activity curves of the selected organs in pig 1 after an injection of 107 MBq 177Lu-OPS201. The uptake in the blood is given in %/L.
At day 0, three WB and SPECT\CT scans were performed in the first 3 h. For better visualization and since the percentage activity values of three
scans in day 0 were quite similar for the selected organs, we show only the data of scan 3 for day 0. Since the percentage administered activity
value of the heart and bladder at days 3 and 12 is less than 1 × 10−3, they are not shown in the graph
Table 1 Time-integrated activity coefficients (TIACs—unit, h)
values for the selected organs of each pigs and respective
standard deviations (SD)
Organs Pig 1 Pig 2 Pig 3 Pig 4 Pig 5 Mean ± SD (n = 5)
Whole body 81.73 72.23 60.95 75.09 80.08 74.02 ± 8.24
Remainder 44.63 53.95 41.46 47.32 45.17 46.51 ± 4.66
Liver 4.98 3.48 2.66 4.51 5.57 4.24 ± 1.17
R. kidney 4.76 3.29 4.69 7.82 2.94 4.70 ± 1.93
L. kidney 4.57 4.18 4.11 7.59 3.14 4.72 ± 1.69
Kidneysa 9.34 7.47 8.80 15.40 6.07 9.42 ± 3.58c
Heart 0.53 3.89 0.41 0.79 0.65 1.25 ± 1.48
Bladder contents 0.90 0.43 0.02 5.27 0.51 1.43 ± 2.17
Spine 4.03 0.57 1.42 0.29 4.16 2.10 ± 1.87
Boneb 21.22 3.00 7.47 1.55 21.91 11.03 ± 9.86
Red marrow 0.12 0.01 0.13 0.22 0.18 0.13 ± 0.08
aSum of both kidneys
bDerived from spine values (19 % of the total skeleton mass)
cMean ± SD values for the kidneys without pig 4 values are 7.92 ± 1.46 h
Beykan et al. EJNMMI Research  (2016) 6:50 Page 6 of 9
human and an animal are used to scale the TIACs. In em-
pirical approaches like the BSA method, scaling is only
based on body weight [10, 20–22].
For animal studies, there are no well-accepted extrapo-
lation methods. Since scaling most likely would decrease
the values of the TIACs and, consequently, the absorbed
doses, we preferred, for this study, to provide a conser-
vative dose assessment without performing inter-species
scaling.
Based on the results of our study, the amino acid infu-
sion plays an essential role for the kidney protection. Ac-
cording to our data for pig 4, the lack of amino acid
infusion results in a twofold increase of the absorbed
doses to the kidney.
So far, in the literature, one clinical human and one
preclinical mouse model study with 177Lu-DOTA-JR11
(OPS201) [10, 12] have been published. In the human
pilot study with 177Lu-DOTA-JR11 (OPS201) by Wild et
al. [10], before the injection of approximately 1 GBq of
177Lu-DOTA-JR11 (OPS201) and 177Lu-DOTA-octreotate,
an amino acid infusion of arginine and lysine was injected
to the four patients for kidney protection. A sixfold higher
tumor-to-kidney ratio was observed for the antagonist
177Lu-DOTA-JR11 (OPS201) compared to the agonist
177Lu-DOTA-octreotate. The absorbed dose to the kid-
neys, the main organ-at-risk after treatment of neuroen-
docrine tumors with DOTA-labeled compounds [2], was
around 50 % higher for the antagonist than for the agonist
177Lu-DOTA-octreotate. Although the kidney doses for
177Lu-DOTA-JR11 (OPS201) were reported as 1.5 times
higher and the patients in this study already had grade 2
or 3 chronic renal failure, no additional decrease in tubu-
lar kidney function was reported. According to the results
of their study, patients’ kidney doses should be monitored
carefully after the second treatment cycle in order not to
reach critical organ dose and to avoid further side effects.
Direct comparison between the results of our study
and the study in humans by Wild et al. [10] may not be
appropriate since the patients in this study had 2 or 3
cycles of treatment and showed already chronic renal
Table 2 Absorbed doses (mGy/MBq) obtained by using the TIACs of the considered organs and respective standard deviations (SD)
Target Organ Pig 1 Pig 2 Pig 3 Pig 4 Pig 5 Mean ± SD (n = 5)
Adrenals 6.82E−02 7.69E−02 6.12E−02 7.39E−02 6.69E−02 6.94E−02 ± 0.01
Brain 5.80E−02 6.74E−02 5.24E−02 5.90E−02 5.88E−02 5.91E−02 ± 0.01
Breasts 5.59E−02 6.74E−02 5.14E−02 5.87E−02 5.66E−02 5.80E−02 ± 0.01
Gallbladder wall 6.61E−02 7.55E−02 5.91E−02 7.08E−02 6.61E−02 6.75E−02 ± 0.01
LLI wall 6.06E−02 7.10E−02 5.49E−02 6.55E−02 6.10E−02 6.26E−02 ± 0.01
Small intestine 6.20E−02 7.25E−02 5.65E−02 6.65E−02 6.21E−02 6.39E−02 ± 0.01
Stomach wall 6.13E−02 7.23E−02 5.61E−02 6.55E−02 6.13E−02 6.33E−02 ± 0.01
ULI wall 6.19E−02 7.24E−02 5.64E−02 6.62E−02 6.20E−02 6.38E−02 ± 0.01
Heart wall 1.10E−01 4.44E−01 9.35E−02 1.38E−01 1.23E−01 1.82E−01 ± 0.15
Kidneysa 2.71E+00 2.17E+00 2.55E+00 4.46E+00 1.76E+00 2.73E+00 ± 1.03
Liver 2.37E−01 1.68E−01 1.27E−01 2.17E−01 2.64E−01 2.03E−01 ± 0.05
Lungs 5.94E−02 7.10E−02 5.39E−02 6.19E−02 6.01E−02 6.13E−02 ± 0.01
Muscle 5.89E−02 6.92E−02 5.36E−02 6.20E−02 5.93E−02 6.06E−02 ± 0.01
Ovaries 6.10E−02 7.16E−02 5.54E−02 6.60E−02 6.14E−02 6.31E−02 ± 0.01
Pancreas 6.57E−02 7.60E−02 5.95E−02 7.09E−02 6.51E−02 6.74E−02 ± 0.01
Red marrow 2.17E−01 7.72E−02 1.05E−01 7.00E−02 2.25E−01 1.39E−01 ± 0.08
Osteogenic cells 1.34E+00 3.75E−01 5.73E−01 2.76E−01 1.38E+00 7.89E−01 ± 0.53
Skin 5.58E−02 6.62E−02 5.11E−02 5.85E−02 5.64E−02 5.76E−02 ± 0.01
Spleen 6.48E−02 7.48E−02 5.95E−02 7.13E−02 6.34E−02 6.68E−02 ± 0.01
Testes 5.73E−02 6.81E−02 5.24E−02 6.16E−02 5.79E−02 5.95E−02 ± 0.01
Thymus 5.84E−02 7.21E−02 5.35E−02 6.12E−02 5.92E−02 6.09E−02 ± 0.01
Thyroid 5.85E−02 6.91E−02 5.34E−02 6.04E−02 5.92E−02 6.01E−02 ± 0.01
Urinary bladder wall 2.44E−01 1.58E−01 5.78E−02 1.15E+00 1.64E−01 3.55E−01 ± 0.45
Uterus 6.13E−02 7.19E−02 5.53E−02 6.96E−02 6.14E−02 6.39E−02 ± 0.01
Total body 1.02E−01 8.76E−02 7.64E−02 8.87E−02 9.98E−02 9.09E−02 ± 0.01
aThe range of kidney absorbed doses was 1.8−2.7 Gy/GBq; the kidney dose value of pig 4 was 4.5 Gy/GBq due to lack of amino acid infusion. The kidney
absorbed dose value of pig 4 was not eliminated from the mean absorbed dose calculation
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failure. The range of kidney absorbed doses for pigs 1–3
and 5 was 1.8–2.7 Gy/GBq. Although the absorbed doses
were high in our study compared to human study (over-
estimation related to inter-species differences), 5GBq
177Lu-OPS201 can be safely administered to the patients
at least two times without reaching the critical organ
dose for the kidney. After the second cycle of the treat-
ment, the absorbed doses need to be analyzed to deter-
mine the injected amount of activity for further cycles.
Presently, there is an ongoing clinical phase I study
(EudraCT #: 2015-002867-41) which aims at finding the
optimum treatment dosage in humans.
In the study by Dalm et al. [12], mice received one
therapeutic injection of 177Lu-DOTA-JR11 (OPS201).
Although the absorbed dose and TIACs values were not
presented in their study, they reported comparable re-
sults to the pilot human study. The follow-up time in
their mouse study was rather short especially for dosi-
metric and quantitative purposes. In comparison to
small animals such as mice or rats, the pig model studies
show more similar physical properties and biodistribu-
tion compared to human physiology. In addition, mul-
tiple blood samples can be easily drawn in pigs
compared to rodents and biodistribution studies for dos-
imetry assessments of therapeutic agents can be carried
out over a longer period compared to rodents.
Conclusions
In general, in vivo distributions and absorbed doses
of 177Lu-OPS201 in pigs are comparable with the lit-
erature. According to the present data, based on an
animal model and extrapolation to humans, the ex-
pected radiation exposure in a human study is accept-
able. However, for therapeutic applications in humans,
the potential inter-species differences need to be ana-
lyzed carefully due to inconsistent spine and spleen
uptake results. In the animals, 177Lu-OPS201 was well
tolerated and produced no abnormal physiological or
behavioral signs. Formation of metabolites in plasma
or urine could not be observed. Consequently, the
analysis of the presented experimental data provides
no evidence that patients enrolled in a 177Lu-OPS201
study would be exposed to an unjustified overexpos-
ure of the radioactivity.
Endnotes
1In the literature, often also called “DOTA-JR11”.
2In the literature, often also called “NODAGA-JR11”.
Additional file
Additional file 1: Table S1. Radioactivity in whole blood and plasma.
Table S2. Plasma metabolites analysis results. Table S3. Organ uptake
values.
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